Skip to main content
Atrás
BRCTF logo

BioArctic AB (publ)

Calidad de datos: 100%
BRCTF
OTC Healthcare Biotechnology
$33.02
$0.00 (0.00%)
Cap. Mercado: 2.93B
Rango del Día
$33.02 $38.00
Rango de 52 Semanas
$15.49 $38.06
Volumen
200
Promedio 50D / 200D
$34.65 / $29.90
Cierre Anterior
$33.02

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 2.9 0.3
P/B 1.5 2.9
ROE % 71.4 3.7
Net Margin % 51.1 3.8
Rev Growth 5Y % 204.7 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $0.00
$0.00 – $0.00
5.9 B 0
FY2029 $25.26
$15.23 – $38.31
4.5 B 1
FY2028 $6.68
$4.03 – $10.14
2.4 B 1

Puntos Clave

Revenue grew 204.66% annually over 5 years — strong growth
ROE of 71.38% indicates high profitability
Net margin of 51.14% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Negative free cash flow of 0.0
P/E of 2.87 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
204.66%
Revenue (1Y)674.85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
71.38%
ROIC50.31%
Net Margin51.14%
Op. Margin68.44%

Seguridad

Debt / Equity
0.04
Current Ratio4.78
Interest Coverage36.10

Valoración

P/E Ratio
2.87
P/B Ratio1.49
EV/EBITDA1.44
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 674.85% Revenue Growth (3Y) 79.92%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 110.91%
Revenue Growth (5Y) 204.66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.99B Net Income (TTM) 1.02B
ROE 71.38% ROA 39.70%
Gross Margin 97.04% Operating Margin 68.44%
Net Margin 51.14% Free Cash Flow (TTM) 0.0
ROIC 50.31% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.04 Current Ratio 4.78
Interest Coverage 36.10 Dividend Yield 0.00%
Valuation
P/E Ratio 2.87 P/B Ratio 1.49
P/S Ratio 1.47 PEG Ratio -0.04
EV/EBITDA 1.44 Dividend Yield 0.00%
Market Cap 2.93B Enterprise Value 1.96B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.99B 257.35M 616.00M 228.29M 23.15M
Net Income 1.02B -177.08M 229.25M -11.18M -119.79M
EPS (Diluted) 11.52 -2.00 2.59 -0.13 -1.36
Gross Profit 1.94B 230.37M 526.37M 153.97M -31.92M
Operating Income 1.36B -228.51M 252.64M -17.44M -139.72M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.57B 1.11B 1.19B 858.31M 897.73M
Total Liabilities 606.62M 216.74M 139.50M 72.07M 109.05M
Shareholders' Equity 1.96B 894.94M 1.05B 786.24M 788.68M
Total Debt 72.24M 54.23M 4.98M 10.04M 15.88M
Cash & Equivalents 1.04B 512.93M 611.57M 805.39M 848.41M
Current Assets 2.48B 1.01B 1.15B 820.84M 861.79M
Current Liabilities 519.47M 175.66M 124.97M 70.88M 101.27M

Puntuaciones de Estrategias

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
#15 of 76
76
#54 of 203
50

Actividad Reciente

Entró Capital Heavy Grower
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026
Entró Value Investing (Warren Buffett)
Mar 24, 2026